The North America Lancets Market is experiencing robust growth, driven by increasing diabetes prevalence and technological advancements in blood sampling devices. The market is forecasted for significant expansion through 2035 due to evolving patient needs and innovation from key manufacturers.
The economic impact of tariffs on "North America Lancets Market".
Market Growth Drivers
Increasing Diabetes Prevalence: The rising incidence of diabetes across the United States and Canada is a major growth driver for the North America lancets market. According to Abbott Laboratories, the growing diabetic population necessitates regular blood glucose monitoring, boosting the demand for lancets for painless and efficient blood sampling.
Advancements in Lancet Technology: Leading companies such as B. Braun Melsungen AG are innovating lancet designs to enhance patient comfort and reduce blood sampling pain. These advancements, including thinner needles and adjustable depth settings, increase the acceptance and usage rates, thereby fueling market growth.
Market Trends
Increased Adoption of Self-Monitoring: The North American market is witnessing a trend toward personalized healthcare, with more individuals performing blood glucose monitoring at home. Companies like Roche Diagnostics are expanding their lancet product lines targeting home users, a shift accelerated by pandemic-driven telehealth adoption.
Sustainable & Eco-Friendly Lancets: There is a trend toward eco-friendly and biodegradable lancet options spurred by environmental regulations. BD (Becton, Dickinson and Company) has introduced recyclable lancet devices, reflecting the growing focus on sustainable healthcare solutions among both suppliers and consumers.
Market Opportunity
Rising Geriatric Population: The aging population in North America presents a significant opportunity for lancet manufacturers. Companies like Owen Mumford Ltd. are developing senior-friendly lancet devices with ergonomic designs for easy handling, aiming to capture this expanding user base.
Strategic Collaborations: Companies are forming strategic partnerships to increase R&D investments and expand their distribution networks. For example, recent collaborations between medical device manufacturers and pharmacies are helping lancet brands penetrate new demographics.
North America Lancets Market Revenue (USD Million), 2020-2035
The North America Lancets Market demonstrated sustained growth from 2020 to 2025, with revenue increasing from $390 million in 2020 to $540 million in 2025. Between 2026 and 2035, the market is projected to experience continued, accelerated growth, reaching $1,100 million by 2035. The upward trend is attributed to increasing prevalence of diabetes, enhanced home-based care, and ongoing product innovations. The steepest growth is expected post-2028, coinciding with new product launches and broader adoption of self-monitoring healthcare devices across the region.
North America Lancets Market by Region Share (%), 2025
In 2025, the United States dominated the North America Lancets Market, accounting for 68% of total market share, followed by Canada at 18%. Mexico represents 7%, while rest of North America and the Caribbean make up 4% and 3% respectively. The dominance of the US can be attributed to high healthcare spending, vast patient pool, and presence of major manufacturers. Canada’s share is bolstered by universal healthcare access. Mexico and other regions are expected to witness moderate growth driven by expanding healthcare infrastructure.
Recent Developments in North America Lancets Market (Last 6 months)
In March 2024, BD (Becton, Dickinson and Company) announced the launch of BD Microtainer® Ultra 2.0, an enhanced version of their minimally invasive lancet system with improved safety features. This launch marks a significant step in patient comfort and care, providing healthcare professionals with effective solutions for reduced pain and better blood collection.
In April 2024, Abbott partnered with Walgreens to optimize the retail distribution of its lancet devices in over 7,000 pharmacy locations across the United States. This strategic partnership aims to improve patient access and convenience, aligning with the broader trend of point-of-care diagnostics and at-home health management.
In May 2024, Ascensia Diabetes Care received FDA clearance for its next-generation contour lancet device, which features a user-friendly design and enhanced safety mechanisms. This development strengthens Ascensia’s portfolio and positions the company as a strong competitor in the technologically advancing North American lancets market.
Press Releases